For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The LANCE® Ultra Human IgG Detection Kit is designed for detection and quantitation of human IgG in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
The glycoprotein immunoglobulin G (IgG), a major effector molecule of the humoral immune response in human, accounts for about 75% of the total immunoglobulins in plasma of healthy individuals whereas IgM, IgA, IgD and IgE, each of which has characteristic properties and functions, constitute the remaining 25%. The basic IgG molecule has a four-chain structure, comprising two identical heavy (H) chains and two identical light (L) chains, linked together by interchain disulfide bonds. Four IgG subclasses have been identified showing their most conspicuous differences in the amino acid composition and structure of the 'hinge region'. The present kit recognizes total IgGs Fc fragment.
| Assay Target | IgG |
|---|---|
| Assay Target Class | Antibody |
| Automation Compatible | Yes |
| Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
| Experimental Type | In vitro |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Biologics/Bioprocess |
| Unit Size | 10,000 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
